More Articles

Access and Evidence

Gold Standard: Standardizing RWD

Nicola Davies, (Jan 4, 2019)

If real-world data is to deliver on its promise, it needs to be standardized
Commercial

Releasing Pharma’s Potential

Adam Chapman, (Jan 3, 2019)

The industry has a new frontier in its sights. LEO Pharma’s CEO provides us with a blueprint to get there.
Commercial

Commercialising Data: The Great Conundrum

Ross Davies, (Jan 1, 2019)

Big data might be everywhere, but its commercial use across pharma is still wanting. Sales and advanced analytics shouldn’t be mutually exclusive
Commercial

You Had Me At Hello

Lucy Fulford, (Jan 1, 2019)

Sophisticated customer engagement is a not a nice-to-have but a core expectation in 2019. How far along is pharma?
Commercial

It’s All About The Journey, Not The Destination

Lucy Fulford, (Jan 1, 2019)

Gone are the days of dumping content and hoping HCPs engage with it. A personalized journey is the roadmap to success
Access and Evidence

Blockchain: Solution Or Snake Oil?

Ross Davies, (Dec 19, 2018)

The potential of blockchain to better manage RWE and access makes it an exciting prospect. However, pharma first needs to get its head around the practical application.
Patients and Medical

Has Medical Affairs Become A Victim Of Its Own Success?

Ross Davies, (Dec 18, 2018)

As medical affairs mushrooms, new skills and capabilities are urgently needed.
Commercial

Pills? What pills?

Adam Chapman, (Dec 13, 2018)

Three ‘Without The Pill’ Digital Therapeutics You Need To Know About
Patients and Medical

Growing Pains

Hugh Gosling, (Dec 12, 2018)

How companies are scaling up their patient-centric efforts
Access and Evidence

VBCs: Are They Working?

Adam Chapman, (Dec 12, 2018)

Are value-based contracts actually improving patient access to new medicines?

Pages